Industry Experts To Advise Biotech on Partnering Strategies, Pitfalls at BIO-Windhover 2003 Conference

WASHINGTON, D.C. (March 25, 2003) – Next month’s BIO-Windhover 2003 conference in Washington, D.C. will highlight the key issues biotech companies face in attempting to partner with other biotech firms and with the pharmaceutical industry and how to overcome potential obstacles based on the experiences of today’s industry experts.

BIO-Windhover 2003: The Partnering Conference for Decision Makers, which will be held April 14-16 at the Ritz-Carlton in Washington, D.C., is uniquely useful to the biotech industry in that state-of-the-art computer technology will be employed to match biotech and pharmaceutical companies --- based on their business capabilities and needs --- with the most appropriate potential industry partners. The conference, which was conducted for the first time in 2002, provides an exclusive forum for pharmaceutical and biotech deal-making executives to meet.

More than 400 attendees are expected, including leading executives from: Amgen Inc., AstraZeneca Pharmaceuticals LP, Aventis Pharmaceuticals Inc., Bayer Corporation, Biogen, Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Celera Genomics, Chiron Corporation, Chugai Pharma USA, LLC, Eli Lilly and Company, Forest Laboratories, Inc., GlaxoSmithKline, Hoffmann-La Roche Inc., IDEC Pharmaceuticals, Johnson & Johnson, H. Lundbeck A/S, Merck & Co., Inc., Monsanto Company, Novartis Pharmaceuticals Corporation, Pfizer Inc., Pharmacia Corporation, Schering-Plough Corporation, Solvay S.A. and Wyeth Pharmaceuticals.

The conference will feature two plenary panel sessions, including:

What Big Pharma Wants from Biotech

WHEN: Tuesday, April 15, 8:30 a.m.-10:00 a.m.
WHERE: Salon I, The Ritz-Carlton Ballroom
WHO: Jan Lundberg, Ph.D., executive vice president, head of Global Discovery Research, AstraZeneca Pharmaceuticals LP
Tony Ford-Hutchinson, Ph.D., executive vice president, World Wide Basic Research, Merck & Co., Inc.
Lee Babiss, Ph.D., vice president, Pre-clinical Research, Hoffmann-La Roche Inc.

The Specifics of Dealmaking
WHEN: Wednesday, April 16, 8:30 a.m.-10:00 a.m.
WHERE: Salon I, The Ritz-Carlton Ballroom
GlaxoSmithKline/Cytokinetics: Creating the Draft-Pick Model for Sharing Targets in a Collaboration
WHO: John Keller, Ph.D., vice president, Business Development, World Wide Business Development, GlaxoSmithKline
Robert Blum, senior vice president, Finance and Corporate Development, and chief financial officer, Cytokinetics, Inc.
Aventis/Genta: When is the Right Time to Partner?
WHO: Michael Yeomans, Ph.D., vice president, head of Global Business Development, Aventis Pharmaceuticals Inc.
Thomas Burger, vice president, Corporate Development, Genta Inc.
Pfizer/Neurocrine: The Marketing Aspects of 2002’s Biggest Collaboration
WHO: Greg Duncan, vice president, Marketing, Pfizer Inc.
Kevin Gorman, Ph.D., vice president, Corporate Development, Neurocrine Biosciences, Inc.

The BIO-Windhover conference was developed, at the behest of business development executives, to address the growing need for a more productive deal-making process for the biotech industry. To meet this need, BIO and Windhover Information Inc., a leading health-care publisher, have developed a computer-based screening system in which biotech and pharmaceutical companies complete a form describing their specific therapeutic, technological or clinical development needs. If a match occurs and the two parties agree, the BIO-Windhover software schedules private, one-on-one meetings.

For more information on BIO-Windhover 2003, please visit or

BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations in all 50 U.S. states and 33 other nations. BIO members are involved in the research and development of health-care, agricultural, industrial and environmental biotechnology products.

# # #